On the contrary, in another retrospective cohort of 230 EGFR-mutant BM NSCLC patients, the addition of WBRT to EGFR TKIs compared to EGFR TKIs alone did not result in significant differences in intracranial PFS (7.4 vs. 6.9, p = 0.23) or systemic PFS (7.9 vs. 7.5, p = 0.55), and combined treatment was associated with worse survival (26.4 vs. 21.6 months, p = 0.049) (129). This evidence concerns the gene EGFR and non-small cell lung carcinoma.